PATENT CLAIM ANALYSIS

Application Number: 15868432
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["424", "172100"]

Abstract:
Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.

Claim (Index 1):
A method of treating cancer comprising administering at least one immune checkpoint inhibitor, wherein the immune checkpoint inhibitor comprises an antibody specific for at least one of CTLA-4, PD-1, TIM-3, LAG-3, PD-L1, B7-H3, B7-H4, BTLA, ICOS, or OX40, and at least one retinoid active agent wherein the at least one retinoid active agent comprises a first Retinoic Acid Receptor (RAR) active agent that is a RAR\u03b1 selective antagonist of general formula (I) wherein R 1 , R 2 , R 3 , and R 6  are independently H or C 1-6  alkyl; R 4  and R 5  are independently H or F; Ar is phenyl, pyridyl, thienyl, furyl, or naphthyl; X is C(CH 3 ) 2 , O, S, or NR 7 , wherein R 7  is H or C 1-6  alkyl; X 1  is H or halogen such as F, Cl or Br; and R 8  is H or OH.

Metadata:
- Claim Count in Document: 46.0
- Percentile: 86.0
- Lexical Diversity: 1.16
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15868459', '15868450', '15620411', '15868469', '14507730']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7856458629890927
- 35 USC 102 Novelty (BERT): 0.6223749112105809
- Combined Prediction Score: 0.7693187678112414
- Mean Citation Score: 499.682388
- Max Citation Score: 559.3043
- Similarity Product: 549.9392989564776

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test